|
Patent landscape, scope, and claims: |
Executive summary
US Patent 11,744,832 claims an oral sustained-release method for treating graft-versus-host disease (GVHD) using a specific small-molecule active: 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (and salts), with optional narrowing to (3R) enantiomer, unit dosage tablets or capsules, enteric coating, dose ranges, and specific excipient lists. The claim set is a typical formulation-method patent strategy: it does not claim the compound’s discovery chemistry directly, but anchors exclusivity around oral, sustained-release dosing of the defined compound for GVHD, with multiple downstream claim fallbacks aimed at harder-to-design-around product formats.
Note: A complete landscape (other US patents, family members, claim charts, Orange Book tie-ins, litigation, and estimated remaining term) cannot be produced from the claim text alone without the patent record (publication number, assignee, filing dates, and prosecution history) and verifying documents. The analysis below is limited to claim scope and design-around implications inherent in the provided claims.
United States Patent 11,744,832 scope: oral sustained-release GVHD method claims for 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
US 11,744,832 is structured as a method-of-treatment claim that is explicitly tied to a formulated oral sustained-release pharmaceutical composition and then narrows that formulation across dependent claims (stereochemistry, unit dose form, tablet vs capsule, enteric coating, dose window, and excipient compositions).
What exactly does claim 1 cover: method for GVHD using oral sustained-release compound and salts?
Independent claim 1 requires all elements:
- Indication: treating graft versus host disease in a patient in need thereof.
- Drug substance: administering a pharmaceutical composition comprising a compound defined as:
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile or pharmaceutically acceptable salts.
- Route and dosage form behavior: composition is suitable for oral administration and provides sustained release of the compound or salt.
- Carrier: includes a pharmaceutically acceptable carrier.
Scope consequences
- The claim does not require a particular mechanism of action, dosing frequency, or specific sustained-release technology (matrix, osmotic pump, beads, etc.). It only requires the composition be “suitable” for oral administration and “provides sustained release.”
- The claim is broad with respect to:
- salt choice (any pharmaceutically acceptable salt),
- sustained release architecture (as long as it provides sustained release),
- patient subgroup (no adult/pediatric limitation, no GVHD severity constraint visible from claim text).
How much is left open by claim 1 if a generic uses a different excipient?
Claim 1 does not define specific excipients. Dependent claims 8–11 add excipient examples, but those are not required for claim 1. That means a manufacturer can potentially use different oral excipient systems and still infringe claim 1 as long as the composition provides oral sustained release and contains the defined compound/salt.
Which enantiomer is required: does US 11,744,832 demand the (3R) form?
Does claim 2 narrow claim 1 to (3R)-enantiomer?
Claim 2 depends on claim 1 and requires:
- compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile or pharmaceutically acceptable salt.
Scope implications
- If a product uses the racemate or a different stereochemical composition, it may avoid claim 2 but may still fall under claim 1 if the claim construction allows the compound definition in claim 1 to cover the non-stated stereochemical form. The independent claim text as provided does not expressly limit stereochemistry, so claim 1 likely remains reachable.
- If prosecution history later limits claim 1 to a specific stereoisomer, that would affect infringement. That information is not provided here.
What unit dosage and solid form are covered: tablet vs capsule vs enteric-coated?
Are unit dosage forms required in the broader patent?
Claims 3–6 impose additional product-format requirements:
- Claim 3: unit dosage form.
- Claim 4: unit dosage form is a tablet.
- Claim 5: unit dosage form is a capsule.
- Claim 6: unit dosage form further comprises an enteric coating.
Risk mapping by dosage form
- A sustained-release oral regimen that uses a non-unit format (e.g., powder sachets, oral suspensions) is potentially a design-around against claims 3–6, but not necessarily claim 1.
- A solid form like tablet or capsule tends to fall within claims 3–5 if it is a unit dosage and sustained release.
- Enteric coating is an additional narrowing limitation in claim 6, so it is only required for infringement of claim 6 specifically.
Key point: These are dependent claims. Product-format changes may reduce exposure to narrower claims while leaving exposure to claim 1 (oral sustained release + defined compound + GVHD method) intact.
What dosage quantities are claimed: does US 11,744,832 specify a mg range?
Is there an explicit dosage range limitation?
Claim 7 depends on claim 2 and requires:
- unit dosage form is a unit dosage; compound is (3R);
- dose from about 5 to about 1000 mg of the compound or salt.
Scope implications
- A very low-dose (sub-5 mg per unit) or a high-dose (over 1000 mg per unit) product could avoid claim 7 while still potentially infringing other claims (notably claim 1 and claim 2 depending on stereochemistry and other features).
- If a competitor proposes multiple dosage strengths, the mg range still likely captures most commercially typical daily strengths as unit doses.
Which excipients are listed: does the patent claim specific formulation recipes?
What excipients are recited in dependent claims?
Claim 8 depends on claim 2 and adds a list of excipients selected from:
lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
Claim 9 adds: microcrystalline cellulose.
Claim 10 adds: lactose.
Claim 11 adds: microcrystalline cellulose and lactose.
Scope consequences
- Claims 8–11 are narrower than claim 1 and appear to function as:
- fallback coverage if an accused product uses common direct-compression or wet-granulation excipient systems,
- proof-oriented drafting aligned with common formulation embodiments.
- However, claim 1 remains the largest hook because it does not specify excipients. If a product uses non-listed excipients (e.g., different disintegrants/binders, different controlled-release polymers), it may avoid dependent claims but could still infringe claim 1 if sustained release and oral route are satisfied.
What is the practical infringement test: sustained release + oral administration + exact compound definition + GVHD method?
How the claim ties to clinical use and not manufacturing steps
These are method-of-treatment claims, so infringement risk typically turns on:
- evidence that the accused product is administered to treat GVHD, and
- evidence that the administered product is an oral sustained-release formulation containing the defined compound or salt.
What does “suitable for oral administration” mean operationally?
This language can cover products marketed for swallowing/oral use, including fixed-dose regimens intended for oral dosing. If a competitor sells an oral formulation but uses a different clinical label, claim validity may still matter because method-of-use infringement can depend on actual use, not solely labeling, depending on jurisdiction and enforcement approach.
What qualifies as “sustained release” for infringement purposes?
The claims do not define a release profile, dissolution specification, or time-to-50% release. That leaves room for expert characterization. A competitor can design around by using:
- immediate release (no sustained release),
- a different release profile not meeting the court’s or fact-finder’s understanding of sustained release,
- non-oral delivery (bypassing “suitable for oral administration”).
Those design-arounds may reduce claim coverage but may create other IP exposure (other patents covering alternate release forms, or non-oral dosing).
Design-around paths specifically targeted to the dependent limitations
Avoiding stereochemistry: racemate or other enantiomer
- To target claim 2 and claim 7 (which depend on claim 2), use a formulation with a different stereochemical composition than (3R).
- Exposure to claim 1 still exists because the independent claim 1 as provided does not state (3R).
Avoiding unit dosage / enteric coating
- Use a format that is not a unit dosage form (for example, multi-dose liquid formulations). This aims at claims 3–6.
- Avoid enteric coating to target claim 6.
Avoiding the mg per unit range
- Select a dosing strength that falls outside ~5 to ~1000 mg per unit to target claim 7.
Avoiding the listed excipients
- Replace lactose and microcrystalline cellulose to avoid claims 9–11.
- Replace listed excipient families to target claim 8.
But because those excipients are not required by claim 1, these changes mainly narrow exposure to dependent claims unless the formulation also stops being an oral sustained-release composition containing the defined compound.
What the claim set suggests about the patent’s strategic intent
The dependent claim ladder is consistent with an IP strategy that:
- secures exclusivity at the highest level (claim 1) for oral sustained-release GVHD treatment using the defined compound, and
- adds layered fallback coverage for common commercial embodiment choices (unit tablets/capsules, enteric coating, typical excipient systems, and a broad mg range).
The claim set is not limited to a specific formulation technology. That broadness increases likelihood that multiple sustained-release oral dosage forms fall within the same patent’s literal claim scope.
Key claim-to-feature matrix (US 11,744,832 as provided)
| Claim |
Core therapeutic purpose |
Required active |
Oral sustained release |
Extra narrowing limitations |
| 1 |
Treat GVHD |
Defined compound or salt |
Yes |
None on unit dose, excipients, stereochemistry |
| 2 |
Treat GVHD |
(3R)-defined compound or salt |
Yes (via claim 1) |
Adds stereochemistry |
| 3 |
Treat GVHD |
From claim 2 |
Yes |
Unit dosage form |
| 4 |
Treat GVHD |
From claim 2 |
Yes |
Tablet |
| 5 |
Treat GVHD |
From claim 2 |
Yes |
Capsule |
| 6 |
Treat GVHD |
From claim 2 |
Yes |
Enteric coating |
| 7 |
Treat GVHD |
From claim 2 |
Yes |
5 to 1000 mg per unit |
| 8 |
Treat GVHD |
From claim 2 |
Yes |
Excipient selection includes common listed excipients |
| 9 |
Treat GVHD |
From claim 2 |
Yes |
Microcrystalline cellulose |
| 10 |
Treat GVHD |
From claim 2 |
Yes |
Lactose |
| 11 |
Treat GVHD |
From claim 2 |
Yes |
Microcrystalline cellulose + lactose |
USPTO prosecution and patent estate scope: what cannot be concluded from claims alone
A full “patent landscape” requires at least: publication number, assignee, priority date(s), related family members, and whether there are continuation/divisional patents. The claim set provided does not supply:
- whether US 11,744,832 is part of a larger family with additional formulation patents (e.g., other sustained-release matrices, immediate-release, different coatings),
- expiration dates and remaining term by priority,
- whether other claims in the granted patent include composition claims vs method claims beyond the ten dependent claims supplied.
Because those items are not in the record here, a quantified landscape is not supportable.
Key Takeaways
- US 11,744,832 claim 1 is the primary infringement anchor: an oral sustained-release method for GVHD using the defined compound (or salts) plus a pharmaceutically acceptable carrier. It does not require specific excipients, unit-dose format, or a particular stereoisomer.
- Dependent claims 2, 3–6, and 7 narrow product embodiments: (3R) enantiomer, unit dosage, tablet vs capsule, enteric coating, and a 5 to 1000 mg per unit range.
- Dependent claims 8–11 capture common formulation recipes with a long excipient list and specific fallbacks for microcrystalline cellulose and lactose.
- The strongest design-around lever is breaking the claim’s required combination: not an oral sustained-release formulation, not the specified compound/salt, or not used for GVHD.
- Excipient swaps and solid-form changes primarily affect the dependent claims, not necessarily claim 1 exposure.
FAQs
-
What product attributes are most likely to meet “sustained release” under US 11,744,832?
Oral dosage forms engineered to extend drug release over time (matrix, controlled-release coatings, bead-based systems) are generally the highest-risk category absent a defined release test in the claims.
-
If a competitor uses the same compound but immediate release instead of sustained release, does US 11,744,832 still apply?
Claim 1 requires oral sustained release. Immediate release aims to avoid a core limitation.
-
Can a competitor avoid claims 9–11 by eliminating lactose and microcrystalline cellulose?
Yes for those dependent claims specifically. Claim 1 still remains a risk unless the formulation stays within the oral sustained-release definition.
-
Does the patent require enteric coating for infringement?
No. Enteric coating is only required for dependent claim 6.
-
How does the 5 to 1000 mg per unit range affect generic or biosimilar-style dosing strategies?
It is specific to claim 7. Outside that range may reduce risk for claim 7 while leaving claim 1/2 exposure if the rest of the limitations are met.
References
- Provided patent claim text for US Patent 11,744,832 (user-supplied).
More… ↓
⤷ Start Trial
|
